Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity [0.03%]
活化的T细胞外泌体DNA转导可增强抗原呈递和抗癌免疫作用
Mengying Hu,Di-Ao Liu,Inbal Wortzel et al.
Mengying Hu et al.
Antigen processing and presentation (APP) is essential for adaptive immunosurveillance. We uncover a mechanism whereby activated T cell-derived extracellular vesicles (ATEVs) drive a positive feedback loop that enhances antigen presentation...
Tissue tension fosters macrophage-driven lipid peroxidation-induced DNA damage [0.03%]
组织张力通过巨噬细胞驱动的脂质过氧化诱导的DNA损伤发挥作用
Mary-Kate Hayward,Jason J Northey,Valentina Opazo-Mellado et al.
Mary-Kate Hayward et al.
Inflammation can induce mutagenic DNA damage to enhance cancer risk and progression. Inflammation also increases fibrosis and stromal stiffening that promotes malignancy, and tissues with higher cancer risk are often stiffer. Despite this c...
T cell extracellular vesicles go nuclear to turn cold tumors hot [0.03%]
T细胞胞外囊泡通过进入核内将“冷”肿瘤转化为“热”肿瘤
Siyu Ji,Haopeng Wang
Siyu Ji
In this issue of Cancer Cell, Hu et al. demonstrate that activated T cell extracellular vesicles (ATEVs)transfer genomic DNA into dendritic cells and tumor cells via granzyme B-mediated nuclear delivery, boosting antitumor immunity. Combine...
A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma [0.03%]
胰腺导管腺癌恶性肿瘤的保守再上皮化程序
Meilian Zhuo,Yong Li,Yifeng Zhang et al.
Meilian Zhuo et al.
Pancreatic intraepithelial neoplasia (PanIN) is common in healthy individuals, but can progress to invasive pancreatic ductal adenocarcinoma (PDAC). PanIN cells spread non-invasively throughout pancreatic ducts, while PDAC is defined by the...
Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes [0.03%]
解析乳腺癌脑转移的细胞架构发现预后不同的免疫图谱
Lena Jassowicz,Fangyoumin Feng,Rolf Warta et al.
Lena Jassowicz et al.
Breast cancer brain metastases (BCBM) are a severe condition with high demand for improved personalized treatment, but a comprehensive understanding of BCBM immune-microenvironment heterogeneity and susceptibility to immunotherapy is lackin...
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial [0.03%]
一种新型选择性ROS1抑制剂(JYP0322)可以克服非小细胞肺癌中的ROS1 G2032R 耐药突变：I期临床试验结果
Yuxiang Ma,Jinhui Xue,Fangfang Gao et al.
Yuxiang Ma et al.
Targeted therapies against ROS1-rearrangements face limitations due to resistance mutations, brain metastases, and central nervous system toxicities. We have developed a next-generation, brain-penetrant ROS1 inhibitor, JYP0322, that can ove...
Rodrigo Entrialgo-Cadierno,Konstantina Morali,Iker Feliu et al.
Rodrigo Entrialgo-Cadierno et al.
About 25% of cholangiocarcinoma (CCA) tumors harbor KRAS mutations. Here, we investigated the activity of RAS(ON) multi-selective inhibitors, which target the active, GTP-bound state of mutant and wild-type variants of canonical RAS isoform...
Xiangliang Yuan,Dihua Yu
Xiangliang Yuan
In this issue of Cancer Cell, Jassowicz et al. integrate multimodal profiling of 156 breast cancer brain metastases (BCBMs), challenging the prevailing perception that BCBMs are uniformly immune cold. The study reveals two distinct immune n...
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors [0.03%]
千余例肿瘤的驱动基因变异图谱及其瘤种特异性分析
Chaitanya Bandlamudi,Daniel Muldoon,Ino de Bruijn et al.
Chaitanya Bandlamudi et al.
Published Erratum
Cancer cell. 2026 Apr 18:S1535-6108(26)00217-5. DOI:10.1016/j.ccell.2026.04.006 2026
Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01 [0.03%]
ICARUS-LUNG01：针对内吞、耐药和反应的靶向治疗见解
Haishuang Sun,Shen Zhao,Jing Li et al.
Haishuang Sun et al.
In this issue of Cancer Cell, Planchard et al. report results from ICARUS-LUNG01, a phase 2 study assessing clinical activity and biomarkers of datopotamab deruxtecan in previously treated non-small cell lung cancer (NSCLC). This study cont...